Stocks › ORMP

ORAMED PHARMACEUTICALS INC.

ORMP·Nasdaq·United States United States·USD
$3.57
-0.12 (-3.25%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
ORMP
ORAMED PHARMACEUTICALS INC. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
ORMPS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of ORMP by members of U.S. Congress · 4 on record
All congressional trades →
PoliticianStockTypeFiledTraded
Brad KnottBrad KnottHouse · R · NC ORMPORAMED PHARMACEUTICALS INC. · Stock Sale
$15,001 - $50,000
Feb 25, 2025 Jan 10, 2025 Filing ↗
Andrew R. GarbarinoAndrew R. GarbarinoHouse · R · NY ORMPORAMED PHARMACEUTICALS INC. · Stock Sale
$1,001 - $15,000
Jan 14, 2022 Jan 14, 2022 Filing ↗
Andrew R. GarbarinoAndrew R. GarbarinoHouse · R · NY ORMPORAMED PHARMACEUTICALS INC. · Stock Sale
$1,001 - $15,000
Nov 3, 2021 Oct 1, 2021 Filing ↗
Andrew R. GarbarinoAndrew R. GarbarinoHouse · R · NY ORMPORAMED PHARMACEUTICALS INC. · Stock Purchase
$1,001 - $15,000
May 24, 2021 Apr 23, 2021 Filing ↗

Whale Activity

Position changes in ORMP reported for 2026-09-30 by 103 institutional filers
Increased: 33New: 18Held: 23Decreased: 17Closed: 10No prior filing: 2
  • Increased33
  • New18
  • Held23
  • Decreased17
  • Closed10
  • No prior filing2
FilerSharesValueChange
MERCER GLOBAL ADVISORS INC /ADV3.8M$17.8Mincreased
Aquamarine Financial (Cayman) Ltd2.7M$12.4Mincreased
Murchinson Ltd.2.1M$10.0Mincreased
Gem Investment Advisors, LLC2.0M$9.3Mheld
BlackRock, Inc.1.8M$8.6Mincreased
BML Capital Management, LLC884.4K$4.1Mincreased
BOOTHBAY FUND MANAGEMENT, LLC820.6K$3.8Mincreased
GEODE CAPITAL MANAGEMENT, LLC500.9K$2.3Mincreased
STATE STREET CORP466.7K$2.2Mincreased
RENAISSANCE TECHNOLOGIES LLC294.3K$1.4Mincreased
VANGUARD PORTFOLIO MANAGEMENT LLC239.1K$1.1Mincreased
Rathbones Group PLC233.0K$1.1Mheld

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by ORMP insiders, by quarter · Form 4
-250.0K-125.0K0125.0K250.0K2025 Q1: 02025 Q12025 Q2: 02025 Q22025 Q3: 02025 Q32025 Q4: 02025 Q42026 Q1: 02026 Q12026 Q2: 02026 Q22026 Q3: -210.4K2026 Q32026 Q4: -50.0K2026 Q4

Recent Insider Transactions

266 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Gabay AvrahamChief Financial Officer Sale −20.0K $4.51 $90K Oct 1, 2026 Form 4 ↗
Hexter JoshuaCOO & CBO Sale −30.0K $4.51 $135K Oct 1, 2026 Form 4 ↗
KIDRON NADAVPresident and CEO · Director Grant / award +368.8K — — Sep 24, 2026 Form 4 ↗
KIDRON NADAVPresident and CEO · Director Grant / award +349.5K — — Sep 24, 2026 Form 4 ↗
Hexter JoshuaCOO & CBO Grant / award +209.3K — — Sep 24, 2026 Form 4 ↗
Hexter JoshuaCOO & CBO Grant / award +75.5K — — Sep 24, 2026 Form 4 ↗
Kidron MiriamChief Scientific Officer · Director Grant / award +209.3K — — Sep 24, 2026 Form 4 ↗
Kidron MiriamChief Scientific Officer · Director Grant / award +208.1K — — Sep 24, 2026 Form 4 ↗
Gabay AvrahamChief Financial Officer Grant / award +209.3K — — Sep 24, 2026 Form 4 ↗
Hexter JoshuaCOO & CBO Option exercise +50.0K $3.69 $185K Jul 2, 2026 Form 4 ↗
Hexter JoshuaCOO & CBO Sale −137.0K $4.46 $611K Jul 1, 2026 Form 4 ↗
Gabay AvrahamChief Financial Officer Sale −73.4K $4.51 $331K Jul 1, 2026 Form 4 ↗
KIDRON NADAVPresident and CEO · Director Tax withholding −44.8K $3.31 $148K Mar 30, 2026 Form 4 ↗
Kidron MiriamChief Scientific Officer · Director Tax withholding −435.1K $3.31 $1.4M Mar 30, 2026 Form 4 ↗
Kidron MiriamChief Scientific Officer · Director Grant / award +119.6K $0.00 $0 Mar 17, 2026 Form 4 ↗
KIDRON NADAVPresident and CEO · Director Grant / award +167.0K $0.00 $0 Mar 17, 2026 Form 4 ↗
Hexter JoshuaCOO & CBO Grant / award +95.9K $0.00 $0 Mar 17, 2026 Form 4 ↗
Gabay AvrahamChief Financial Officer Grant / award +95.9K $0.00 $0 Mar 17, 2026 Form 4 ↗
KIDRON NADAVPresident and CEO · Director Gift −100.0K $0.00 $0 Mar 12, 2026 Form 4 ↗
KIDRON NADAVPresident and CEO · Director Option exercise +109.0K $0.00 $0 Jan 22, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding ORMP · SEC Form N-PORT
FundSharesValue% of fundAs of
iShares Russell 2000 ETF
iShares Trust
634.6K$3.1M0.00%Jun 30, 2026
Fidelity Small Cap Index Fund
Fidelity Salem Street Trust
378.5K$1.5M0.00%Jul 31, 2026
iShares Russell 2000 Value ETF
iShares Trust
318.6K$1.5M0.01%Jun 30, 2026
VANGUARD RUSSELL 2000 INDEX FUND
VANGUARD SCOTTSDALE FUNDS
194.0K$974K0.01%Aug 31, 2026
iShares Micro-Cap ETF
iShares Trust
115.0K$553K0.04%Jun 30, 2026
Schwab Small-Cap Index Fund
SCHWAB CAPITAL TRUST
83.6K$340K0.00%Jul 31, 2026
Master Small Cap Index Series
Quantitative Master Series LLC
63.6K$306K0.01%Jun 30, 2026
Goldman Sachs ActiveBeta(R) U.S. Small Cap Equity ETF
Goldman Sachs ETF Trust
58.0K$291K0.03%Aug 31, 2026
Avantis U.S. Small Cap Equity ETF
American Century ETF Trust
55.6K$279K0.01%Aug 31, 2026
Fidelity Small Cap Value Index Fund
Fidelity Salem Street Trust
48.7K$234K0.01%Jun 30, 2026

Mutual funds and ETFs whose N-PORT filings list ORMP's shares (CUSIP 68403P203), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • Aquamarine Financial (Cayman) LtdSCHEDULE 13G/A · passive (13G) · 2.7M shares6.4%
    Nov 13, 2026 · ↗
  • Aquamarine Financial (Cayman) LtdSCHEDULE 13G/A · passive (13G) · 2.5M shares6.0%
    Aug 14, 2026 · ↗
  • Leonard Braden MichaelSCHEDULE 13G/A · passive (13G) · 1.0M shares2.5%
    Jun 29, 2026 · ↗
  • BML Investment Partners, L.P.SCHEDULE 13G/A · passive (13G) · 866.3K shares2.1%
    Jun 29, 2026 · ↗
  • Aquamarine Financial (Cayman) LtdSCHEDULE 13G · passive (13G) · 2.0M shares5.1%
    May 15, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming ORAMED PHARMACEUTICALS INC. as client

No lobbying filings found naming ORAMED PHARMACEUTICALS INC. as the client.

Government Contracts

Federal awards to ORAMED PHARMACEUTICALS INC. · USAspending

No federal contract awards found for ORAMED PHARMACEUTICALS INC..

U.S. Patents

Recent USPTO applications naming ORAMED PHARMACEUTICALS INC.

No USPTO patent applications found for ORAMED PHARMACEUTICALS INC..

Annual Financials

From ORMP's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$2.0Mn/a$1.3M$2.7M$2.7M
Operating income-$15.1M-$12.8M-$15.8M-$40.6M-$24.2M
Net income$64.0M-$19.1M$5.1M-$36.6M-$23.0M
Diluted EPS$1.50-$0.48$0.14-$0.94n/a
Operating cash flow-$9.1M-$8.4M-$10.3M-$27.9M-$21.2M
Cash and equivalents$45.9M$54.4M$9.1M$40.5M$77.2M
Total assets$230.9M$155.3M$220.6M$161.6M$128.0M
Shareholders' equity$199.7M$146.3M$163.8M$151.8M$115.8M

As ORAMED PHARMACEUTICALS INC. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Mar 26, 2026 ↗

Stock Splits

Every split and reverse split in the price history
  • 1-for-12Reverse splitJan 23, 2013

Split dates and ratios from the price history · Close Prices from Tiingo.com

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 8.01Other eventsNov 19, 2026
    EDGAR ↗
  • 8-K · Items 5.07Shareholder voteSep 17, 2026
    EDGAR ↗
  • 8-K · Items 5.03, 8.01, 9.01Bylaw amendment · Other eventsJun 30, 2026
    EDGAR ↗
  • 8-K · Items 5.02Officer / director changeDec 31, 2025
    EDGAR ↗
  • 8-K · Items 8.01Other eventsDec 31, 2025
    EDGAR ↗

About ORAMED PHARMACEUTICALS INC.

From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersNEW YORK, NY
IncorporatedDE
Former namesIntegrated Security Technologies, Inc., IGUANA VENTURES LTD